What the FDA does when a cancer drug is approved

This page explains how the Food and Drug Administration (FDA) reviews cancer drugs, what its named cancer programs do, and what the agency can and cannot do for you.

The Food and Drug Administration is big. Cancer sits in one part of it.

That part is called the Oncology Center of Excellence. It was set up on January 19, 2017, under a law called the 21st Century Cures Act. The FDA describes the center as one place that unites its cancer and blood disorder experts. It carries out expedited reviews of products for cancers and blood disorders. It also runs research, education and regulatory programs.

The center states its own goal in one line. It aims to achieve patient-centered regulatory decision-making through innovation and collaboration. Its vision is a unified, collaborative scientific environment for developing and regulating cancer products.

A company that wants to sell a cancer drug in the United States has to bring its evidence to the FDA. Reviewers read it. They look at the studies. They look at the side effects. They decide whether the product should be allowed on the market, and for which use.

That last part matters more than most people expect. An approval is not a general blessing. It is tied to a specific use. A drug approved for one cancer type at one stage is not automatically approved for another.

Your oncologist can still prescribe outside those lines. That is called off-label use, and it is a normal part of medicine. But it is a doctor's decision, not an FDA one.

The center groups much of its work into programs with short names. You may see them in news stories. Here is what a few of them are for.

Project Orbis is about timing across borders. It allows concurrent submission and review of cancer products among international partners.

Project Optimus is about dose. The center describes it as reforming the dose optimization and dose selection paradigm in cancer drug development.

Project Confirm is about follow-through. It promotes transparency of outcomes related to accelerated approvals. Accelerated approval lets some drugs reach the market on early evidence. This program makes it easier to see what happened afterward.

Project Facilitate helps with expanded access requests. These are for when a patient wants an investigational drug (one not yet approved) outside a trial.

Project Patient Voice is a website. It gives patients, caregivers and providers direct access to patient-reported symptom data from cancer clinical trials.

There are more. The center also lists programs for pediatric oncology, rare cancers, older adults, immuno-oncology, and cell and gene therapy.

You can read the official record. When a cancer drug is approved, the approved use and the known risks are published. That gives you a reference point that is not a company brochure.

You can look at reported symptoms. Project Patient Voice shows what patients in trials said about their symptoms. The FDA notes this data may be limited, because the surveys may not capture every symptom. That can turn a vague warning into something concrete you can raise at your next visit.

You can bring a question about expanded access. Project Facilitate exists for that.

And you can use approval news as a prompt. If a new drug was approved in your cancer type, that is a reasonable thing to ask your oncologist about.

It cannot look at your case. The agency does not have your scans, your labs or your history. Nobody there is reviewing your chart.

It cannot tell you which treatment to take. Approval means a product met a standard for a group of patients in studies. It does not mean the product is right for you.

It does not give medical advice. Even Project Patient Voice carries that warning. The FDA says it should not be used on its own to make medical decisions or replace professional medical advice.

It cannot make your insurer pay. Coverage is a separate system with separate rules. This page is based on FDA pages, not on an FDA statement about insurers.

It cannot hand you a drug. The agency regulates products. It does not supply them to patients.

Most people never need to think about the FDA at all. Their oncologist recommends something approved, and that is that.

The times it becomes useful are narrower. You want to know whether a drug is approved for your exact situation. You heard about an approval in the news and want to know if it applies to you. Or standard options have run out, and you are asking what else is legally possible.

In each of those cases the honest first step is the same. Ask your care team. They know your case, and they can tell you where an official record would actually change something.

Details on the agency's programs and contacts do change. It is worth checking the current information on their site before you rely on a specific number or address.